Keywords: ideal, data, astrazeneca, iressa, raises, prospects, non-small

IDEAL data for AstraZeneca's Iressa raises prospects in non-small cell lung cancer

Article | 27 May 2002

Print This

AstraZeneca has reported positive results in its pivotal Phase II trialsprogram for Iressa (ZD1839) in patients with non-small cell lung ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in